期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 180, 期 6, 页码 821-830出版社
WILEY
DOI: 10.1111/bjh.15058
关键词
multiple myeloma; ibrutinib; dexamethasone; Bruton tyrosine kinase
类别
资金
- Pharmacyclics LLC, an AbbVie Company
- NIH/NCI Cancer Center Support [P30 CA008748]
- RJ Corman Multiple Myeloma Research Fund
Novel therapies with unique new targets are needed for patients who are relapsed/refractory to current treatments for multiple myeloma. Ibrutinib is a first-in-class, once-daily, oral covalent inhibitor of Bruton tyrosine kinase, which is overexpressed in the myeloma stem cell population. This study examined various doses of ibrutinib +/- low-dose dexamethasone in patients who received >= 2 prior lines of therapy, including an immunomodulatory agent. Daily ibrutinib +/- weekly dexamethasone 40mg was assessed in 4 cohorts using a Simon 2-stage design. The primary objective was clinical benefit rate (CBR; >= minimal response); secondary objectives included safety. Patients (n=92) received a median of 4 prior regimens. Ibrutinib+dexamethasone produced the highest CBR (28%) in Cohort 4 (840mg+dexamethasone; n=43), with median duration of 9.2months (range, 3.0-14.7). Progression-free survival was 4.6months (range, 0.4-17.3). Grade 3-4 haematological adverse events included anaemia (16%), thrombocytopenia (11%), and neutropenia (2%); grade 3-4 non-haematological adverse events included pneumonia (7%), syncope (3%) and urinary tract infection (3%). Ibrutinib+dexamethasone produced notable responses in this heavily pre-treated population. The encouraging efficacy, coupled with the favourable safety and tolerability profile of ibrutinib, supports its further evaluation as part of combination treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据